7 Hills Pharma

7 Hills Pharma is a clinical-stage pharmaceutical company developing the first-in-concept lactone activators to enhance immunotherapies for the treatment of drug-resistant solid tumors and infectious diseases. Our compounds are novel, first-class systemic integrin activators that have been shown in preclinical models to increase and prolong cell adhesion while maintaining the ability to move and migrate. In this process, 7HP compounds are expected to enhance antigen presentation and immune priming to promote efficient immune responses to various antigens, including those from solid tumors and infectious diseases. The lead compound, 7HP349, an oral VLA-4/LFA-1 allosteric activator, will enter Phase I testing for PD-1 refractory solid tumors and elderly influenza.